B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer

Tropomyosin receptor kinase (TRK) fusions involving neurotrophic receptor tyrosine kinase (NTRK)1, NTRK2, and NTRK3 genes occur in a range of tumor types. Larotrectinib, the first FDA-approved highly selective TRK inhibitor, has demonstrated an overall response rate (ORR) of 75% by independent central review across a broad spectrum of tumors that harbor NTRK gene fusions (Drilon et al., NEJM 2018;378:731–9). Here we report updated data on the...